Table 4 Grade 2 adverse drug reactions and Grade 3–4 adverse events reported in ≥10% of patients overall.

From: Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours

Event term

Grade 2 adverse drug reactions*

Grade 3–4 adverse events

Total

Abdominal pain

3

6

9

Alanine aminotransferase increased

5

4

9

Anaemia

24

6

30

Fatigue

22

5

27

Mucositis oral

7

0

7

Nausea

15

4

19

Neutrophil count decreased

19

23

42

Platelet count decreased

4

4

8

Vomiting

7

5

12

White blood cell decreased

13

8

21

Total

119

65

184

  1. *An adverse drug reaction is an AE that is considered to be causally related to any dose of the 6MP or methotrexate.